# Special Issue

# Predictive and Prognostic Biomarkers for Response to Neoadjuvant Chemotherapy for Breast Cancer

## Message from the Guest Editor

Breast cancer (BC) is the most commonly occurring cancer in women, with 2.26 million new BC cases being diagnosed each year. Recently, BC has come to be considered as a heterogeneous group of tumours with regard to clinical presentation, epidemiology, histology, radiology, gene expression, prognosis, and response to treatment. Subsequently, the management of BC continues to present a significant clinical challenge, considering that these tumours often do not respond to targeted therapeutic agents and are more diverse than we originally thought. Therefore, there is an urgent need to identify new prognostic and predictive features that could accurately sub-stratify BC, monitor and grade responses to chemotherapy, and tailor and guide treatment for individual patients to avoid serious toxicity and the economic burden on health systems caused by unnecessary ineffective therapies. For this Special Issue, submissions of original research articles and reviews are welcome. I look forward to receiving your contributions.

## Guest Editor

Dr. Tarek M. A. Abdel-Fatah

Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK

## Deadline for manuscript submissions

28 February 2026

MDPI

# About the Journal

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## Author Benefits

**Open Access:**
free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)